It’s a Revolution: Real World Data & Patient Health Outcomes
Disease Interception and the US National Cancer Moonshot
Therapeutic Innovation & Regulatory Science (TIRS): Focus on Pharmaceutical Compounding
"A Gathering of Global Proportions" at DIA 2016
FDA’s Accelerated Pathways Are the New Normal
May 2016 — Therapeutic Innovation & Regulatory Science (TIRS): Focus on Pharmaceutical Compounding
Information in Action: A Conversation with Barbara Lopez Kunz
How the DIA, a key industry NGO, is repositioning itself as the go-to place for the independent knowledge-driven insights that drive decisions in a business with no boundaries. One world. One table. Open seating.
R&D Model Mixes Compassion, Calculation
Altruism and self-interest are at the heart of European thinking on neglected diseases.
Drug Compounding: A Cause and Cure for High Drug Prices?
The practice’s emerging-if improbable-cost-saving potential.
Pharmaceutical Executive, April 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive April 2016 issue in an interactive PDF format.
PE eBook Series 2016 Info Sheet
Stand-Out Promotion Strategies for a Crowded Drug Marketplace Spon Opp
Market Access Capabilities for a Value-Driven Marketplace Spon Opp
Surviving in a New Era of Compliance Challenges - Spon Opp
Can FDA Control Drug Prices?
More generics and biosimilars may generate competition - but FDA opposes broad compounding.
Orphans of the Storm
Europe’s contrasting views on rare disease drugs - one bashing pricing abuses, the other extolling their public health virtues - could ultimately leave these products out in the cold.
Pharmaceutical Executive, March 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive March 2016 issue in an interactive PDF format.
How Did Things Get This Bad? Look in the Mirror, US Pharma
As US pharma continues to ponder its “winter of discontent”, the question that leaders of industry have to be asking themselves is, “How did things get this bad?” Tom Norton reports.
PE Strat Outlook 2015
Therapeutic Innovation & Regulatory Science: An Increasingly Global Approach
Pharm Exec AAM 062015
What Lies Ahead 2016
Make the Pain Stop: New Shared Platform Eases Investigators’ Burden
EUPATI Launches Educational Toolbox on Medicines Research & Development
Congress to Keep a Close Watch on FDA
18 February, 2016.
What are YOU Wearing Today? The Present & Future of Wearable Health Devices
The Creative Impulse: Defending Pharma and Health DTC
Defending pharma and health direct-to-consumer advertising is a top 2016 priority for the 4A’s industry trade group.
Pharmaceutical Executive, February 2016 Issue (PDF)
Click the title above to open the Pharmaceutical Executive February 2016 issue in an interactive PDF format.
Harvard Business School Launches Precision Trials Challenge
Harvard Business School has launched a competition to generate ideas to bring precision diagnostics and therapies to market more quickly by reinventing the clinical trials process.
